Medication info

Innoen Hydrochloride Dopamine Premix 80 mg Injection

Prescription medicationInjectionsIntravenous injection
Ingredient · strength
Glucose Monohydrate›5000mg / 100mLDopamine Hydrochloride›80mg / 100mL
Manufacturer / importer
HK Innoen Co., Ltd.
Appearance
Colorless or pale yellow transparent injectable solution contained in a colorless, transparent plastic container.
Packaging
500 milliliters / box
Approval status
Active

MFDS item code 200101331 · Notified 2001.05.04 · Insurance code 640002160

Summary

Main use
Treatment of hypotension due to shock or decreased cardiac output, and decreased urine output
Who receives it
Adults
Adult administration
Adults: Administer dopamine hydrochloride intravenously at 2~5㎍/min per kg of body weight. In severe cases, it may be administered intravenously at 5~10㎍/min per kg of body weight, increasing to 20~50㎍/min per kg of body weight. Adjust the dose appropriately according to age and symptoms. Before administering this drug, administer blood or plasma to achieve a venous pressure of 10~15cmH₂O and a pulmonary wedge pressure of 14~18mmHg. If administering more than 50㎍/min per kg of body weight, measure urine output frequently. During patient treatment, continuously evaluate the treatment approach with respect to blood volume, increased myocardial contractility, and distribution of peripheral vascular perfusion. Adjust according to the patient's response, paying particular attention to decreased urine flow, increased tachycardia, or development of a new arrhythmia, which may indicate that the dopamine dose is being reduced or that the dose is being temporarily maintained. Use caution to control the infusion rate of all potent intravenous drugs and avoid inadvertent bolus administration.

Ingredients

Manufacturer
HK Innoen Co., Ltd.

Efficacy & effects

Treatment of hypotension due to shock or decreased cardiac output, and decreased urine output

  • Myocardial infarction
  • trauma
  • endotoxin sepsis
  • postoperative shock
  • renal impairment shock
  • chronic heart failure shock
  • oliguria
  • anuria
  • hypotension due to decreased cardiac output
View approved original text

This medication is used for symptoms of shock due to myocardial infarction and trauma, endotoxin sepsis, postoperative renal impairment, and chronic heart failure (congestive heart failure), oliguria, and anuria, as well as hypotension due to decreased cardiac output.

How it is given

Adult administration

Adults: Administer dopamine hydrochloride intravenously at 2~5㎍/min per kg of body weight. In severe cases, it may be administered intravenously at 5~10㎍/min per kg of body weight, increasing to 20~50㎍/min per kg of body weight. Adjust the dose appropriately according to age and symptoms. Before administering this drug, administer blood or plasma to achieve a venous pressure of 10~15cmH₂O and a pulmonary wedge pressure of 14~18mmHg. If administering more than 50㎍/min per kg of body weight, measure urine output frequently. During patient treatment, continuously evaluate the treatment approach with respect to blood volume, increased myocardial contractility, and distribution of peripheral vascular perfusion. Adjust according to the patient's response, paying particular attention to decreased urine flow, increased tachycardia, or development of a new arrhythmia, which may indicate that the dopamine dose is being reduced or that the dose is being temporarily maintained. Use caution to control the infusion rate of all potent intravenous drugs and avoid inadvertent bolus administration.

Precautions

This medication should be administered at a reduced dose to patients who have previously taken monoamine oxidase inhibitors. Safety and appropriate dosing have not been sufficiently confirmed for pediatric patients, so its use in children is not recommended. This medication loses its effectiveness in alkaline solutions, and should not be mixed with alkaline diluents. It should not be administered to patients with certain diseases, such as pheochromocytoma, uncontrolled tachyarrhythmia, ventricular fibrillation, hyperthyroidism, and closed-angle glaucoma. Patients with a starch allergy should exercise caution when using solutions containing dextrose. Care should be taken in patients with peripheral vascular disease or sulfite allergy, as this medication may induce asthma attacks in some patients. When administering blood, do not use with dextrose-containing solutions, and caution should be taken for fluid overload and electrolyte imbalances during intravenous infusion. This medication can cause a variety of adverse reactions, such as cardiac arrhythmias, changes in blood pressure, gastrointestinal symptoms, skin reactions, headaches, and anxiety, so patients should be closely monitored. Blood pressure, heart rate, urine output, etc. should be carefully monitored, and if any abnormal signs appear, dose adjustments or discontinuation of administration may be necessary. Rapid discontinuation can cause hypotension, so it should be tapered off gradually. This medication may interact with other drugs, so caution is required when used with anesthetics, antidepressants, beta-blockers, and vasoconstrictors. During pregnancy, the risks and benefits for the fetus should be carefully considered before administration, and during breastfeeding, administration should be avoided if possible, or breastfeeding should be discontinued. The elderly should start at a lower dose considering impaired liver, kidney, and heart function. Overdose may cause elevated blood pressure, so administer at a controlled rate or discontinue, and use alpha-blockers if necessary. To prevent tissue damage at the injection site, administer via a large vein and continuously observe the injection site to prevent extravasation. This medication should not be mixed with alkaline solutions, and the color and condition of the solution should be checked before administration; do not use if abnormalities are found. With long-term use, regularly check the fluid and electrolyte balance and acid-base status, and dosage adjustment should be done with caution.

Side effects

  • ventricular ectopy
  • atrial fibrillation
  • ventricular tachycardia
  • peripheral vascular contraction
  • ectopic pulse
  • tachycardia
  • angina pectoris
  • palpitations
  • shortness of breath
  • hypotension
Show 21 more
  • hypertension
  • ventricular arrhythmia
  • ectopic beats
  • angina pain
  • vasoconstriction
  • abnormal conduction
  • bradycardia
  • QRS widening
  • hypernitrogenemia
  • increased blood pressure
  • nausea
  • vomiting
  • abdominal distension
  • abdominal pain
  • paralytic ileus
  • hair loss
  • headache
  • anxiety
  • phlebitis
  • injection site necrosis
  • oral mucosal changes

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to prevent exposure to air or moisture. It is advisable to maintain storage temperature at general room temperature, which is not particularly cold or hot.

Appearance and packaging

Appearance

Colorless or pale yellow transparent injectable solution contained in a colorless, transparent plastic container.

Package unit

500 milliliters / box

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.